Entrada Therapeutics Long Term Debt

Entrada Therapeutics (TRDA) currently reports a long-term debt of $45M as of March 2026. That compares with $50M in the prior-year period — down 9.9% year over year. Use the charts on this page to explore Entrada Therapeutics's long-term debt history and peer comparisons.

Entrada Therapeutics's long-term debt decreased from $50M to $45M — a 9.9% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entrada Therapeutics reported $45M in long-term debt as of March 2026. That compares with $50M in the prior-year period — down 9.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $45M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entrada Therapeutics, and consider following TRDA for alerts when major investors trade the stock.